File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1021/acsinfecdis.2c00488
- Scopus: eid_2-s2.0-85141984270
- WOS: WOS:000885386000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine
Title | Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine |
---|---|
Authors | |
Keywords | antibody immunodominant site linear epitopes neutralization SARS-CoV-2 variants |
Issue Date | 10-Nov-2022 |
Publisher | American Chemical Society |
Citation | ACS Infectious Diseases, 2022, v. 8, n. 12, p. 2586-2593 How to Cite? |
Abstract | The ongoing coronavirus disease 2019 pandemic has raised concerns about the risk of re-infection. Non-neutralizing epitopes are one of the major reasons for antibody-dependent enhancement. Past studies on the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have revealed an infectivity-enhancing site on the ancestral SARS-CoV-2 spike protein. However, infection enhancement associated with the SARS-CoV-2 Omicron strain remains elusive. In this study, we examined the antibodies induced by a multiple epitope-based vaccine, which showed infection enhancement for the Omicron strain but not for the ancestral SARS-CoV-2 or Delta strain. By examining the antibodies induced by single epitope-based vaccines, we identified a conserved epitope, IDf (450–469), with neutralizing activity against ancestral SARS-CoV-2, Delta, and Omicron. Although neutralizing epitopes are present in the multiple epitope-based vaccine, other immunodominant non-neutralizing epitopes such as IDg (480–499) can shade their neutralizing activity, leading to infection enhancement of Omicron. Our study provides up-to-date epitope information on SARS-CoV-2 variants to help design better vaccines or antibody-based therapeutics against future variants. |
Persistent Identifier | http://hdl.handle.net/10722/329036 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.179 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gong, HR | - |
dc.contributor.author | Hu, YF | - |
dc.contributor.author | Li, XC | - |
dc.contributor.author | Yau, TCC | - |
dc.contributor.author | Zhang, BZ | - |
dc.contributor.author | Huang, JD | - |
dc.date.accessioned | 2023-08-05T07:54:48Z | - |
dc.date.available | 2023-08-05T07:54:48Z | - |
dc.date.issued | 2022-11-10 | - |
dc.identifier.citation | ACS Infectious Diseases, 2022, v. 8, n. 12, p. 2586-2593 | - |
dc.identifier.issn | 2373-8227 | - |
dc.identifier.uri | http://hdl.handle.net/10722/329036 | - |
dc.description.abstract | <p>The ongoing coronavirus disease 2019 pandemic has raised concerns about the risk of re-infection. Non-neutralizing epitopes are one of the major reasons for antibody-dependent enhancement. Past studies on the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have revealed an infectivity-enhancing site on the ancestral SARS-CoV-2 spike protein. However, infection enhancement associated with the SARS-CoV-2 Omicron strain remains elusive. In this study, we examined the antibodies induced by a multiple epitope-based vaccine, which showed infection enhancement for the Omicron strain but not for the ancestral SARS-CoV-2 or Delta strain. By examining the antibodies induced by single epitope-based vaccines, we identified a conserved epitope, IDf (450–469), with neutralizing activity against ancestral SARS-CoV-2, Delta, and Omicron. Although neutralizing epitopes are present in the multiple epitope-based vaccine, other immunodominant non-neutralizing epitopes such as IDg (480–499) can shade their neutralizing activity, leading to infection enhancement of Omicron. Our study provides up-to-date epitope information on SARS-CoV-2 variants to help design better vaccines or antibody-based therapeutics against future variants.<br></p> | - |
dc.language | eng | - |
dc.publisher | American Chemical Society | - |
dc.relation.ispartof | ACS Infectious Diseases | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | antibody | - |
dc.subject | immunodominant site | - |
dc.subject | linear epitopes | - |
dc.subject | neutralization | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | variants | - |
dc.title | Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine | - |
dc.type | Article | - |
dc.identifier.doi | 10.1021/acsinfecdis.2c00488 | - |
dc.identifier.scopus | eid_2-s2.0-85141984270 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 2586 | - |
dc.identifier.epage | 2593 | - |
dc.identifier.eissn | 2373-8227 | - |
dc.identifier.isi | WOS:000885386000001 | - |
dc.identifier.issnl | 2373-8227 | - |